The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Spain: Researchers have found in a real-world cohort of patients with giant cell arteritis–associated aortitis, published in ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biologic, Type of Therapy, End User, Payment Method ...